期刊文献+

尾加压素Ⅱ对培养乳鼠心肌细胞内钙离子的影响及其机制

The effect of urontensin Ⅱ on intracellular calcium concentration of cardiomyocytes in neonatal rat
下载PDF
导出
摘要 目的观察尾加压素Ⅱ(UⅡ)对体外培养乳鼠心肌细胞内钙离子浓度的影响。方法把体外培养的SD乳鼠心肌细胞以Fluo3/AM荧光指示剂负载,分为4组:正常对照组;单纯UⅡ干预组;尼卡地平提前阻断+UⅡ干预组;IP3受体拮抗剂Xestspongin C+UⅡ干预组。应用激光共聚焦显微镜技术检测心肌细胞钙离子浓度变化。结果正常对照组心肌细胞内钙离子荧光强度较低(31.65±2.37);单纯UⅡ干预组钙离子荧光强度增加明显(87.13±5.72);尼卡地平提前阻断+UⅡ干预组以及IP3受体拮抗剂Xestspongin C+UⅡ干预组钙离子也有增加,分别为(59.43±4.76)、(54.79±5.18)。结论UⅡ可引起心肌细胞内钙离子浓度增高,其主要的机制可能与细胞外钙离子内流和肌浆网钙离子释放增加有关。 Objective To observe the effect of urotensin Ⅱ (U Ⅱ) on the intracellular calcium concentration of cardiomyocytes in neonatal rat. Methods The cardiomyocytes of neonatal rat were cultured in vitro and treated with UⅡ. The concentration of intracellular calcium was observed with laser scanning confocal microscope(LSCM). Results The concentration of Ca^2+ in cardiomyocytes was increased shortly after treatment with UⅡ, which was partly abolished before treated with nicardipine and xestspongin C. Conclusion UⅡ can increase the concentration of calcium in cardiomyocytes.
作者 李巍 李爱民
出处 《西部医学》 2009年第2期175-177,共3页 Medical Journal of West China
基金 重庆市自然基金项目(NO:CSTC2007BB5026)
关键词 尾加压素Ⅱ 心肌细胞 激光共聚焦显微镜技术 Urotensin Ⅱ Cardiac myocyte Intracellular free Calcium concentration Laser scanning confocal microscope (LSCM)
  • 相关文献

参考文献1

二级参考文献28

  • 1Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H,Beauvillain JC, et al. Cloning of the cDNA encoding the urotensinⅡ precursor in frog and human reveals intense expression of the urotensin Ⅱ gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 1998; 95: 15803-8.
  • 2Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV,Romanic AM, et al. Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPRI4. Nature 1999, 401: 282-6.
  • 3Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin Ⅱ. Lancet 2002; 359: 1990-7.
  • 4Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, et al. Urotensin-Ⅱ-mediated cardiomyocyte hypertrophy:effect of receptor antagonism and role of inflammatory mediators.Naunyn Schmiedebergs Arch Pharmacol 2004; 370: 238-50.
  • 5Egginger JG, Camus A, Calas A. Urotensin-Ⅱ expression in the mouse spinal cord. J Chem Neuroanat 2006; 31: 146-54.
  • 6Zhang YG, Qi YF, Xia CF, Pang YZ, Yang J, Zhang ZK, et al.Stimulating proliferation of aorta smooth muscle cells of rat byurotensin Ⅱ. Chin Pharmacol Bull 2001; 17: 155-7.
  • 7Shi L, Ding W, Li D, Wang Z, Jiang H, Zhang J, et al. Proliferation and anti-apoptotic effects of human urotensin Ⅱon human endothelial cells. Atherosclerosis 2006; 188: 260-4.
  • 8Watanabe T, Suguro T, Kanome T, Sakamoto Y, Kodate S,Hagiwara T, et al. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 2005; 46: 738-44.
  • 9Russell FD, Molenaar P. Investigation of signaling pathways that mediate the inotropic effect of urotensin-Ⅱ in human heart. Cardiovasc Res 2004; 63:673-81.
  • 10Gruson D, Rousseau MF, Ahn SA, van Linden F, Ketelslegers JM. Circulating urotensin Ⅱ levels in moderate to severe congestive heart failure: Its relations with myocardial function and well established neurohormonal markers. Peptides 2006; 27: 1527- 31.

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部